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The mitotic kinase Aurora1A and its partner protein TPX2 (argeting rotein for 
 kinesin1like protein ), are overexpressed in cancers and it has been proposed that 
they work together as an oncogenic holoenzyme. TPX2 is responsible for activating Aurora1
A during mitosis, ensuring proper cell division. Disruption of the interface with TPX2 is 
therefore a potential target for novel anti1cancer drugs that exploit the increased sensitivity of 
cancer cells to mitotic stress. 
Here, we investigate the interface using co1precipitation assays and isothermal 
titration calorimetry to quantify the energetic contribution of individual residues of TPX2. 
Residues Tyr8, Tyr10, Phe16 and Trp34 of TPX2 are shown to be crucial for robust complex 
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formation, suggesting that the interaction could be abrogated through blocking any of the 
three pockets on Aurora1A that complement these residues. Phosphorylation of Aurora1A on 
Thr288 is also necessary for high1affinity binding and here we identify arginine residues that 
communicate the phosphorylation of Thr288 to the TPX2 binding site. 
With these findings in mind, we conducted a high1throughput X1ray crystallography1
based screen of 1255 fragments against Aurora1A and identified 59 hits. Over three1quarters 
of these hits bound to the pockets described above, both validating our identification of hot1
spots and demonstrating the druggability of this protein1protein interaction. Our study 
exemplifies the potential of high1throughput crystallography facilities such as XChem to aid 
drug discovery. These results will accelerate the development of chemical inhibitors of the 
Aurora1A/TPX2 interaction.  
 

#;1<7=#<;
The human kinome contains many sub1families of structurally or functionally related 
kinases () such as the Aurora kinases. Aurora1A, B and C are serine/threonine kinases with 
high sequence similarity within their catalytic domains, yet each plays a different and 
important role during mitosis ().  
During mitosis Aurora1A localises to the poles of the mitotic spindle and along spindle 
microtubules (	). Here it contributes to centrosome separation, assembly of the mitotic 
spindle and chromosome segregation through phosphorylation of a plethora of substrates (

). Owing to its crucial role in many mitotic steps, inhibition of Aurora1A kinase activity can 
lead to error1prone cell division and cell death (). Aurora1A is frequently overexpressed in 
cancers and is an attractive target for the development of anti1cancer treatments. Many 
ATP1competitive inhibitors of the Aurora kinases have been developed but none have been 
approved for clinical use ().   
There are concerns about the selectivity of ATP1competitive Aurora kinase inhibitors due to 
the similarity between the catalytic domains of the three Aurora kinases. In the case of 
Aurora1A, this has been addressed by exploiting a single amino acid difference in the active 
site ( ). However, an alternative approach to generating Aurora1A inhibitors would be 
valuable in reducing the risk of off1target kinase inhibition. Kinase inhibitors that act through 
an allosteric mechanism, such as trametinib, have very high selectivity towards their target 
(). Though there are currently no potent allosteric inhibitors of Aurora kinases, their 
development could be envisaged based on knowledge of the regulatory mechanisms of 
these proteins such as stabilisation of an inactive conformation or disruption of their 
interactions with upstream activator proteins.  
Page 3 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 3 
The catalytic activity of Aurora1A is regulated by autophosphorylation on Thr288 and 
through interactions with protein binding partners such as TPX2 and TACC3 (). TPX2 
(argeting rotein for  kinesin1like protein ), is the key partner for localising 
Aurora1A to the mitotic spindle () and a recent analysis of the co1expression of these two 
proteins in human cancers suggested that they work together as an oncogenic holoenzyme 
(). TPX2 also strongly activates Aurora1A, increasing its catalytic activity by at least 71fold 
and stimulating autophosphorylation (	
). In cells, mutation of the TPX2 binding site of 
Aurora1A reduces activity and causes mislocalisation (). Furthermore, TPX2 protects 
Aurora1A from dephosphorylation by protein phosphatase 1 (PP1), a function that is 
abrogated by mutation of TPX2 residue Trp34 (). The minimal binding domain of TPX2 
required to interact with Aurora1A is residues 1143 (). The crystal structure of the Aurora1
A/TPX2 complex shows two segments within this region of TPX2 that interact with three 
hydrophobic pockets on the surface of Aurora1A (Figure 1A). Residues 7121 of TPX2 adopt 
an extended conformation that binds to the N1terminal lobe of Aurora1A. Residues 30143 of 
TPX2 form an α1helical segment that binds between the N1 and C1terminal lobes, near the 
activation loop, which is phosphorylated on Thr288 (). A recent structure of TPX2 bound 
to unphosphorylated Aurora1A suggests that only residues 7121 are required for binding 
unphosphorylated Aurora1A ().  
A compound that blocks the interaction between Aurora1A and TPX2 would disrupt 
both the localisation and activity of Aurora1A and would be useful in the validation of the 
Aurora1A/TPX2 complex as a cancer drug target. The identification of ‘hot1spots’ within a 
protein1protein interface can help with the search for a protein1protein interaction (PPI) 
inhibitor (	). Hot1spots have been described as clusters of residues that upon loss of 
functionality (such as through mutation to alanine), cause a significant (at least 2.0 kcal mol1
1) change in the binding free energy of a complex (
). Quantification of the contribution 
of individual residues to the interaction of TPX2 and Aurora1A would allow greater 
understanding of the interaction and allow a more targeted, rational approach to blocking the 
interaction using small molecules.  
Here we set out to identify hot1spot residues in the Aurora1A/TPX2 interaction 
interface, determine the contribution of the α1helical region of TPX2 to the interaction and 
resolve whether the phosphorylation status of Aurora1A affects the affinity of the interaction. 
We then conducted an X1ray crystallography1based fragment screen using the XChem 
facility at Diamond Light Source and identified 59 fragments bound to Aurora1A, the majority 
of which (46 hits) bound somewhere within the TPX2 binding site. The hot1spots identified in 
the Aurora1A/TPX2 interface coincide with major sites of fragment binding.  
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Figure 1. Identification of hot-spots in the Aurora-A/TPX2 interface. (A) Crystal structure of Aurora-A (gray, 
surface) bound to TPX2 (cyan, cartoon, PDB: 1OL5) (21). Residues 122-126 of Aurora-A have been removed for 
clarity. TPX2 residues mutated in this work are coloured purple. The Y-pocket has been coloured yellow, the F-pocket 
coloured orange and the W-pocket pink. (B) SDS-PAGE analysis of co-precipitation assays. GST is present as an 
impurity from the production of GST-tagged TPX2. Representative isothermal titration calorimetry (ITC) traces of the 
binding between Aurora-ACA and TPX2 variants; wild-type (C) and F19A (D).   


-

   
 ! We initially investigated the contribution of a 
subset of residues in TPX2 to Aurora1ACA binding using co1precipitation assays (Figure 1B). 
All tested mutations displayed significantly reduced binding to Aurora1ACA (Table 1, 
Supporting Information). We then used isothermal titration calorimetry (ITC) to determine the 
binding affinities of the interactions between Aurora1A and different variants of TPX2. The 
affinity between Aurora1ACA, phosphorylated on Thr288, and wild1type TPX2 was determined 
to be 269 nM. As with the co1precipitation assay, all of the mutants tested showed 
substantially weaker binding to Aurora1ACA than wild type TPX2, ranging from a 61fold to a 
2901fold reduction of binding (Figure 1C, 1D and Table 1). Broadly speaking, the effect of 
the mutations on TPX2 affinity followed the same trend as seen from the co1precipitation 
assay. The mutations that had the smallest effect on affinity were D11E, F35A and D11N 
showing a 61, 71 and 8.51fold reduction in binding, respectively. Mutations D11A and F16A 
had the next most significant effect on binding with 131 and 171fold reductions in affinity, 
respectively. However, these translate into differences in the Gibbs free energy change 
(∆∆G) of less than 2 kcal mol11 when compared to the wild1type interaction. We therefore do 
not consider these to be hot1spot residues in the interface, but Phe35 and Phe16 may 
instead be considered as solvent1occluding ‘O1ring’ residues adjacent to hot1spot residues. 
The Asp11 mutations remove a hydrogen bond between this residue in the N1terminal 
segment of TPX2 and Trp34 the α1helical segment. Binding affinity was affected most 
significantly by mutations F19A, W34A, Y8A and Y10A which showed reductions of 551, 591, 
2251 and 2901fold, respectively, compared to the native interaction. These correspond to 
∆∆G of at least 2 kcal mol11 relative to the native interaction and thus we conclude that Tyr8, 
Tyr10, Phe19 and Trp34 are hot1spots in the Aurora1A/TPX2 interaction. 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Table 1. Quantification of the binding of different TPX2 variants to Aurora-ACA as determined by co-precipitation and 
ITCa 
 
 
a
WT, wild-type; Ka, binding constant; ΔH and ΔS, enthalpic and entropic terms; T = 293 K; N, the stoichiometry derived from 
the curve fitting of each interaction. An asterisk indicates the stoichiometry was fixed at the stated value; Kd, dissociation 
constant; X-fold reduction in affinity refers to each mutant’s Kd value relative to that of WT TPX2; ΔΔG, difference in Gibbs’ 
Free Energy change relative to wild-type. For the pull-downs, the relative band density values given are the average 
Coomassie gel band densities of three separate experiments relative to wild-type TPX2. The errors are the standard 
deviation between these three band density values. For the ITC experiments, the wild-type condition was performed four 
times and each mutant condition performed once. Errors quoted were given by Origin software upon curve fitting 
(mutants) or are the averages of the experimental errors given by Origin software for each individual experiment (WT). 
 
  
 


! The α1helical segment of TPX2 contacts the 
activation loop of Aurora1A and stabilises a conformation that buries the phosphorylated 
side1chain, suggesting that the phosphorylation status of Aurora1A might influence the 
binding of TPX2 (Supplementary Figure S1A) (). Indeed, the binding affinity between 
TPX2 and unphosphorylated Aurora1ACA was measured to be 91fold weaker than the affinity 
between TPX2 and phosphorylated Aurora1ACA (Supplementary Figure S1B, S1C, 
Supplementary Table S1). The phosphorylated side1chain of Thr288 interacts with a cluster 
of arginine residues, including Arg180 and Arg286, mutation of either of which results in 
binding affinities that are insensitive to the phosphorylation state of the kinase and similar to 
that of the unphosphorylated, unmutated kinase (Supplementary Figure S1C, Table S1). To 
identify which of the regions of TPX2 contributed to sensing the phosphorylation state of 
Aurora1A, we determined the binding affinities of three TPX2 mutants to dephosphorylated 
Aurora1ACA and compared with their affinities for the phosphorylated kinase (Supplementary 
Table S2). The binding affinity of TPX2 mutants D11A and F16A for phosphorylated and 
dephosphorylated Aurora1ACA exhibited a similar fold1reduction as wild1type TPX2 (7.8–9.8 
TPX2 
variant 
Relative 
band density 
Ka  
(10
3
 M
-1
) 
ΔH  
(kcal mol
-1
) 
TΔS 
(kcal mol
-1
) 
ΔG  
(kcal mol
-1
) 
N Kd  
(µM) 
X-fold 
reduction 
in affinity 
ΔΔG 
(kcal 
mol
-1
) 
WT 1.00 ± 0.00 4182.50 ± 635.00 -22.29 ± 0.34 -13.40 -8.88 0.95 0.27 ± 0.04 n/a n/a 
Y8A / 16.60 ± 1.60 -10.71 ± 3.7 1.62 -1.63 1.36 60.81 ± 5.86 225 7.25 
Y10A 0.11 ± 0.07 12.80 ± 0.71 -13.60 ± 0.37 -8.12 -5.48 1.00* 78.37 ± 4.35 290 3.40 
D11A 0.48 ± 0.10 276.00 ± 14.00 -13.77 ± 0.11 -6.48 -7.29 0.98 3.63 ± 0.18 13 1.59 
D11E 0.65 ± 0.18 611.00 ± 31.00 -32.50 ± 0.28 -24.73 -7.77 0.56 1.64 ± 0.08 6 1.11 
D11N 0.66 ± 0.18 439.00 ± 28.00 -4.13 ± 0.05 3.43 -7.56 1.63 2.29 ± 0.15 8.5 1.32 
F16A 0.33 ± 0.18 220.00 ± 15.00 -28.75 ± 0.69 -21.59 -7.16 0.45 4.57 ± 0.31 17 1.72 
F19A 0.14 ± 0.10 67.90 ± 4.20 -38.35 ± 4.67 -31.94 -6.41 0.39 14.78 ± 0.91 55 2.47 
W34A 0.30 ± 0.09 62.90 ± 2.10 -20.70 ± 0.20 -14.24 -6.46 0.86 15.92 ± 0.53 59 2.42 
F35A 0.41 ± 0.14 543.00 ± 22.00 -36.24 ± 0.23 -28.51 -7.73 0.54 1.84 ± 0.07 7 1.15 
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 6 
fold), suggesting that neither of these residues is involved in TPX2 ‘sensing’ the 
phosphorylation state of Aurora1A. TPX2 mutant F35A, however, had less than 21fold 
difference in binding affinity for phosphorylated of dephosphorylated Aurora1ACA. The crystal 
structure of TPX2 residues 1145 bound to unphosphorylated Aurora1A catalytic domain 
shows no density for the α1helical region of TPX2, consistent with its weak interaction at the 
W1pocket in the absence of phosphorylation of the activation loop (PDB code 4C3P) (). 
Thus, we propose that the α1helical region of TPX2 acts as a sensor for the phosphorylation 
state of the activation loop of Aurora1A through interaction with the W1pocket. 
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
  ! Having concluded that the Aurora1A/TPX2 
interaction could be significantly weakened by perturbing any of the three pockets (Y1, F1, or 
W1), we accessed the XChem platform at Diamond Light Source with the aim of conducting 
a fragment screen against Aurora1A to identify compounds bound anywhere along the TPX2 
binding site. In total, we soaked 1255 fragments into Aurora1ACA1ADP crystals from two 
different fragment libraries ( ); the Diamond1SGC Poised Library (DSPL ()) 
numbered 255 fragments (at the time of screening) and a commercially available Maybridge 
set containing 1000 fragments. Our crystals were robust, showing no significant difference in 
diffraction resolution with an increasing amount of DMSO and so 40 % (the top value tested) 
was chosen as the working concentration, allowing final fragment soaking concentrations of 
200 and 80 mM for the DSPL and Maybridge libraries, respectively.  Perhaps because of 
these high soaking concentrations, some crystals were unsuitable for mounting (either the 
drop contained heavy precipitate or the crystal showed damage) and so the number of 
crystals mounted was only 1103. Of those mounted and cryocooled, 944 datasets were 
collected, with an average resolution of 2.2 Å.  
Following data collection, the autoprocessed datasets were analysed with the 
program PanDDA (Pan Dataset Density Analysis) (	), which identified statistically 
significant regions of unmodelled electron density in 184 cases. By manual inspection, 59 
unique fragments bound at allosteric sites on the Aurora1A surface were confirmed, giving a 
total hit rate from our screen of 4.7 % (Supplementary Table S3, Figure 2A). In all cases 
ADP was bound at the active site. 46 of the 59 allosteric hits were bound in the three 
pockets that comprise the TPX2 binding site on Aurora1A, with the Y1pocket particularly well 
sampled with 35 hits (59 % of the total and 76 % of the TPX21relevant hits, Figure 2B). The 
F1pocket contained 10 hits (17 % of the total, 22 % of TPX21relevant hits, Figure 2C) and the 
W1pocket had a solitary binder. The remaining 13 hits (22 % of total) were scattered all 
around the kinase domain of Aurora1ACA, including one small fragment that appeared to be 
coordinated to an Mg2+ ion within the active site.   
 
 
Figure 2. Overview of the crystallographic fragment screen. (A) A representative crystal structure of Aurora-ACA 
(surface, gray) with TPX2 (cyan, cartoon) superposed for illustrative purposes showing the three TPX2-relevant 
binding sites seen following fragment screening. Most of the 59 hits bound in the Y-pocket (yellow), some bound in 
the F-pocket (orange) and a single fragment was bound in the W-pocket (pink) with the remaining hits bound 
elsewhere around the surface of the protein (not shown) (B) View of the Y-pocket. (C) View of the F-pocket. A 
representative structure of a single fragment bound to Aurora-ACA is used in both cases to illustrate the pocket with 
the remaining relevant fragments superposed onto the structure to show the dispersion and breadth of different 
binding modes seen between the hits. 
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 8 
Upon identification of these hits, we triaged the 46 TPX21relevant fragments down to 
just 22 for which the binding was then validated with a variety of orthogonal assays. As both 
of the main binding sites are highly hydrophobic, the first filter we applied during manual 
inspection of the hits was to prioritise any fragments exhibiting any non1hydrophobic 
interactions between ligand and protein. The extremely high fragment concentrations used 
to soak our crystals could have resulted in a number of false positives and so by identifying 
specific, strong interactions (such as hydrogen bonds, salt bridges, π1stacking and halogen 
bonds, by eye and with the use of the Web1based Protein1Ligand Interaction Profiler (PLIP) 
(	)) we eliminated any fragments that were most likely to be non1specific because 
hydrophobicity positively correlates with increased promiscuity of compounds (	). We also 
eliminated any compounds that were not available commercially in the necessary quantities 
for a reasonable price. The third filter was an assessment of the fragments’ drug1like 
properties and attractiveness from a medicinal chemistry point of view. This triage process 
left 22 fragments that we repurchased, although we were unable to source the original 
fragment in two cases (labelled with an asterisk in Table 2) and used a close analogue 
instead. The first orthogonal validation assay, NMR1STD, confirmed that the majority of the 
22 purchased fragments bound to Aurora1ACA with 8 (fragments 4, ?, 4, 4(, 4,, 42, 4? and 
) not showing an STD response (Supplementary Figure S2, Supplementary Table S4).  
 
In parallel, we carried out a fragment1based screen of 1000 compounds (a 
commercially available collection from Maybridge) against Aurora1ACA using NMR1STD. To 
prevent binding of fragments to the active site, these experiments were carried out in the 
presence of an ATP1competitive inhibitor, CCT137690 (		) and then hits were classified as 
any fragment showing a reduced STD response in the presence of TPX2, since this would 
imply competition for the TPX2 binding site. 47 such hits were identified, with decreases in 
STD response ranging from 88 % to 5 % (Supplementary Figure S3). We selected 5 
fragments exhibiting the most significant decreases in STD response. Affinities for Aurora1
ACA in the M1mM range were measured for each of these fragments, both alone and in the 
presence of CCT137690, suggesting allosteric binding sites for all five (Supplementary 
Table S5). Four of the five fragments had been included in the X1ray crystallography screen 
described above without registering as hits, demonstrating the well1known lack of 
consistency between different screening methodologies (	
). We attempted to determine 
their binding sites using X1ray crystallography but despite collecting good quality X1ray 
datasets from crystals soaked with each of the five compounds, we found no evidence of 
bound fragments. We therefore decided to focus on the 22 compounds for which 
crystallographic data were available. 
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Using ITC, we obtained binding curves for 15 of the 22 fragments with affinities 
ranging from 15 M to 3.75 mM (Supplementary Figure S4). The effect of each fragment on 
the autophosphorylation of Aurora1ACA was then determined (Supplementary Figure S5). In 
this assay, each fragment was incubated with unphosphorylated Aurora1ACA, TPX2 and ATP 
for an hour. Using an antibody specific for Aurora1A phosphorylated at Thr288 its activation 
loop we were able to quantify the effect of the fragments: 3 showed inhibition, 7 showed 
activation and the remaining 12 fragments showed no significant effect on Aurora1ACA 
autophosphorylation. Finally we tested the effect of the fragments on the catalytic activity of 
Aurora1ACA  using the ADP1QuestTM assay, which measures turnover of ATP (	). Using this 
assay in kinetic mode, we determined IC50 values for 8 of the 22 fragments against Aurora1
ACA alone, ranging between 18 M and over 2 mM (Supplementary Figure S6). IC50 values 
could not be measured for five of these eight fragments against the Aurora1ACA/TPX2 
complex, suggesting the binding site competition from TPX2 in these cases was too great for 
the fragment to show an effect. In all but one case the fragment IC50 was higher against the 
Aurora1ACA/TPX2 complex than for Aurora1ACA alone, which would be expected for 
fragments competing for the binding site of a protein with much higher affinity. The TPX2 
concentration in this assay was only twice its Kd for Aurora1A (600 nM versus 270 nM) 
whereas fragment concentrations were up to 1001fold higher, which could explain why IC50 
values were seen for the fragments against the Aurora1ACA/TPX2 complex when perhaps no 
binding would have been expected. 
Table 2. Summary of binding data collected for the 22 fragments selected for validation following the 
crystallography-based fragment screena 
 
Frag No. Pocket 
K
d
 
(μM) 
IC
50
 
(μM) 
% Activation  Frag No. Pocket 
K
d
 
(μM) 
IC
50
 
(μM) 
% Activation 
1 W 15 18 / 64 69  12 Y 432 245 / † 154 
2 F - - 106  13 Y 2792 - 108 
3 F - - 105  14 Y 494 1105 / - 125 
4 F - † / † 103  15 Y 1821 † / † 108 
5 Y 170 899 / - 188  16* Y 3753 - 88 
6 Y - † / - 131  17 Y 1665 - 106 
7 Y 894 † / - 91  18 Y 410 108 / 107 48 
8 Y 1297 † / - 93  19 Y - - 111 
9 Y 796 - 77  20* F 619 1302 / † 259 
10 Y - 308 / 425 90  21 Y 681 - 141 
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11 Y 357 407 / † 60  22 F - - 127 
a
Kd, dissociation constant; IC50, the concentration at which half maximal kinase activity was seen; % Activation, the relative band density compared 
to a DMSO-containing control condition quantified from a Western blot. A dash indicates that no binding (ITC) or inhibition (activity assay) was seen. 
A cross indicates that the calculated IC50 was higher than 2 mM, the highest assay concentration. The first IC50 value refers to Aurora-A
CA
 alone and 
the second to the Aurora-A
CA
/TPX2 complex. In all ITC experiments, the stoichiometry between fragment and protein (N) was fixed upon curve 
fitting at a value of 1.00, with the exception of fragment 1 for which this did not result in adequate fitting to the data (N=0.43:1). All ITC and kinase 
activity experiments were performed at least in duplicate, the Western blot assay was performed in triplicate. An asterisk next to a Frag No. 
indicates the purchased fragment used for these assays is a close analogue of the original crystallographic hit. 
 
Fragment 4which was the only hit found in the W1pocket, initially appeared to be the 
most promising hit (Table 2, Figure 3). Located between the catalytically important αC and 
αE helices, in the centre of the area to which the α1helical domain of TPX2 binds, a pocket 
in the surface of Aurora1A had opened up to allow the fragment to interact with the usually 
buried Cys247. Initially we could not fit the fragment into the visible electron density with any 
confidence and it was only upon recognising that the fragment contained an isothiazolone 
ring that the binding mode of the fragment became clear. Thiol groups, such as on cysteine 
side1chains, are able to cleave the N–S bond of thioazolone rings and form a covalent 
disulfide bond with the new non1cyclic product (Figure 3A) as seen in our structure (Figure 
3B) (	). Despite strong inhibition of Aurora1ACA in two different assays, a Hill slope gradient 
of greater than 2 against both Aurora1ACA and the Aurora1ACA/TPX2 complex was observed, 
possibly indicating aggregation, non1specific binding of the fragment, or activity through 
binding to multiple sites (	). This was also observed in the biochemical assay data 
associated with some of the other fragments (e.g. 4@A and it is possible that these fragments 
interact with the ATP binding pocket. However, fragment 4belongs to a class of well1known 
‘PAINS’ compounds (	) and so we decided not to investigate or develop this further.  
 
Figure 3. A thiazoline compoud bound to the W-pocket. (A) Reaction scheme for the formation of a covalent 
disulphide between fragment 1 and the thiol of Cys247 on Aurora-A. (B) Crystal structure of fragment 1 bound to 
Aurora-ACA clearly showing the disulphide bond. The side chain of Lys250 has been removed for clarity. The final 
2mFo-DFc electron density map is shown as a wire mesh for the fragment and the side chain of Cys247 contoured to 
1.0 σ. 
 
 The top six fragments (,, 44, 4, 4), 49 and @) were selected for a competition 
assay to determine whether they inhibited the interaction between Aurora1A and TPX2  
(Figure 4, 5). The affinity of the interaction between Aurora1ACA and TPX2 was measured in 
the presence of each of the top six fragments at a concentration of 3 or 4 times their Kd 
values (Figure 5). In all six cases the measured Kd between Aurora1A
CA and TPX2 was 
weakened compared to the affinity in the absence of compound, with or without DMSO. 
Fragments 4 and 4) had the least effect on the affinity of the Aurora1ACA/TPX2 complex, 
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fragments , and 44 both caused a two1fold reduction in affinity, and fragment 18 incubation 
caused an approximately 51fold reduction in affinity.  Fragment @ had the strongest 
inhibitory effect, a 12.51fold reduction in affinity between Aurora1ACA and TPX2. Strikingly, 
the fragment with the greatest effect in this assay was the only one to bind in the F1pocket, 
but curiously it had the lowest affinity for Aurora1A (Table 2). In contrast, among fragments 
that bound to the Y1pocket, affinity for Aurora1A was correlated with strength of Aurora1
A/TPX2 interaction inhibition, with the exception of fragment 4. We conclude that the 
binding mode, as well as the affinity for Aurora1A, determines the effect on the Aurora1
A/TPX2 interaction, and that both pockets should be explored further as targets for the 
development of inhibitors. 
 
Figure 4. The chemical structures of the top 6 hit fragments identified through our high-throughput X-ray 
crystallography based screen against Aurora-A. The crystal structure (and corresponding PDB accession code) of 
each fragment bound to Aurora-A is shown with its final 2mFo-DFc electron density map shown as a blue wire mesh 
contoured at 1.0 σ. The equivalent data for the remaining 16 repurchased fragments is shown in Supporting 
Information Figure S7. 
 
 
Figure 5. Determination of the affinity between Aurora-A and TPX2 in the presence of fragments. (A) The Kd values 
measured by ITC between Aurora-ACA and TPX2 in the presence of buffer alone (‘Control’), buffer containing 5 % 
DMSO (‘DMSO’) and each of the top 6 fragments at a concentration of 3 or 4 times their Kd value against Aurora-ACA. 
(B) ITC traces of the binding of Aurora-ACA to TPX2 in the presence of each of the top 6 fragments. 
     
7

!Most of the validated fragment hits from our screen bound 
to the ‘Y1pocket’, and mutation of the region of TPX2 that complements this pocket (TPX2 
mutants Y10A, Y8A) caused the largest loss of affinity for any TPX2 mutant tested. 
Compounds that bind this pocket and disrupt the interaction with TPX2 have been described 
by us and others, and targeting this pocket could provide a strategy for the development of 
Aurora1A/TPX2 inhibitors (	).  However, the Y1pocket is analogous to the PDK11interacting 
fragment (PIF) pocket, an important regulatory site in the AGC family of kinases (
). It is 
therefore critical to investigate what degree of selectivity could be achieved with compounds 
that bind with high affinity to this site.   The base of the pocket is made of a patch of 
hydrophobic residues with a surrounding ‘wall’ of charged residues. Most of the hits lie flat 
above the base of the pocket forming downward hydrophobic contacts, and in some cases 
groups branch off the core of the compounds and make specific interactions with 
surrounding residues. Only one or two compounds explore the space past Tyr199 where the 
hydrophobic groove extends across the back of the kinase towards the ‘F1pocket’, the
second major binding site for fragment hits.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The shallow and expansive nature of protein1protein interactions contrasts with the 
small, deep, well1defined clefts that are ideal binding sites for small molecules, making PPIs 
challenging targets in drug discovery. (
). However, the large number of hits found in both 
the Y1 and the F1pockets from our fragment screen suggests that the PPI between Aurora1A 
and TPX2 is potentially druggable. From our results, it might appear that the Y1 and F1
pockets have a higher hit rate than the W1pocket, and therefore present a better opportunity 
for drug discovery. However, the nature of our screen contained an inherent bias: in the 
crystal form of Aurora1ACA used, the Y1 and F1pockets face a solvent channel, which would 
allow easy access to these sites for the soaked fragments while the W1pocket, located 
between the αC and αE helices of Aurora1A, is much closer to a crystal contact position and 
as such is less accessible. To definitively probe the druggability of this pocket, another 
crystal form of Aurora1A should be used in which there is unhindered access of solvent to 
the W1pocket site. The use of X1ray crystallography as the primary screening method in 
fragment1based drug discovery is dependent for its success on the availability of a crystal 
form in which the binding site of interest is not occluded by crystal contacts. Another solution 
to this problem is to use NMR1based fragment screening. Indeed, we identified hits through 
NMR screening that were validated by ITC, but unfortunately could not be located in a 
crystal structure.  
 
The compound ‘AurkinA’ was recently reported as binding to the Y1pocket of Aurora1A (	). 
It was discovered following a fluorescence anisotropy1based screen and subsequent 
structure1activity1relationship driven optimisation of the original hit compound.  It binds to 
Aurora1A with a Kd of 4 M, inhibits its kinase activity and mislocalises Aurora1A from the 
mitotic spindle in HeLa cells in a manner that suggests the compound does abrogate the 
Aurora1A/TPX2 interaction. The crystal structure of the Aurora1A/AurkinA complex shows the 
compound bound in the Y1pocket in a different conformation to any of our Y1pocket fragment 
hits. Rather than laid flat across the floor of the pocket, AurkinA lies upright against the ‘back 
wall’. Overlaying the compound with the structure of TPX2 bound to Aurora1A shows very 
similar positioning between Tyr8 of TPX2 and a central aromatic ring of AurkinA.  A second 
group has recently reported small molecule inhibitors of the Aurora1A/TPX2 interaction. The 
three most potent compounds had Kd values against Aurora1A in the 12115 M range (
). 
Initially identified through a virtual screen of the interface (focussed on the Y1pocket), binding 
to Aurora1A was confirmed using surface plasmon resonance and the compounds were 
shown to compete with TPX2 for binding to the kinase. Collectively, we have demonstrated 
the feasibility of targeting the Y1pocket of Aurora1A and inhibiting its interaction with TPX2 
 and . The breadth of compounds now reported suggests that the Y1pocket is 
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druggable. In addition, we have reported a number of F1pocket binders and the single W1
pocket binder, some of which affect Aurora1A activity. Finding hits in these additional 
pockets shows the power and sensitivity of X1ray crystallography as a primary fragment 
screening technique. The top six fragment hits described here have been taken forward for 
optimisation with the aim of developing a small molecule inhibitor of the Aurora1A/TPX2 
interaction. The development of such compounds is a priority to enable validation of the 
interaction between Aurora1A and TPX2 as a potential drug target in cancer. 
   
">-<7.
Full details of methods are provided in the Supplementary Information. 


! Protein Data Bank accession codes for the crystal structures of Aurora1
ACA in complex with the following fragments: 4B,<1$AB,<1;A(B,<1<A)B,<1A,
B,<11A2B,<1.A8B,<1A9B,<1'A?B,<10A4@B,<1A44B,<1CA4B,<1DA4(
B,<.@A4)B,<.4A4,B,<.A42EB,<.(A48B,<.)A49B,<.,A4?B,<.2A@EB,<.7A
4B,<.>AB,<.6A!

*;<0$>7/>">;.
 This work was funded through the following grants to R.B: MRC CASE industrial 
studentship (MR/K016903) and Cancer Research UK Programme Awards (C24461/A12772 
and C24461/A23302). Funding was provided for L.V and V.V by the Ministry of Education, 
Youth and Sports of the Czech Republic (LK11205 and LO1304). We would like to thank our 
colleagues in Leicester, J. Basran and C. Dominguez for assistance with the ITC, and F. 
Muskett for assistance with NMR experiments. We would also like to acknowledge LifeArc 
(Formerly MRC Technology) for contributing funding towards to the PhD position of P.J.M. 
We thank Diamond Light Source for access to beamline i0411 (proposal lb14331) that 
contributed to the results presented here. 
 
..<#>7<;>;
.
#

 
The Supporting Information is available free of charge on the ACS Publications website at 
  
 Methods, Tables S11S5, Figures S11S7. 
 


: The authors declare that they have no conflicts of interest with the 
contents of this article. 

 
Page 14 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 14
1>6>1>;>.
 
 	
								 !
"#! $!%!	&'&()
 *		 +,	* ( #$$$ ! !% ! "	

	-)'-.)
( !	 *	 
	 	 /0"!1	 	 !	 2	 *	 3	 4 
$$#	 	 *!	 5	
!		6$  		6	*&&-7!  !" +!#
,#!!#$$##$' 	0! $#!0$
1!$10 !$!# $0$	..8'.8
) 
	 	  6	 * &&& 5!93 $ '$ "	  , !#!# %$ !%
!#'!"	(.&'(:
. !		6#	5		5	!$		;!	3	5$!	6/#!1
,0%!5!5"	&88'&-)
: %	  
	 +#	 < 5	 	 = 5	 $	  =	 "!1	 >	 *		

$1	=	!	=	#"	<<	4!	6<		+	$$				
!	
	;!	<		
	!		?		!$	<	
*$0!	 * @ 8 5! #1 !% 42-.)	  !$$ #1 $$'!$#$
0!!%5!5"	

 	):')
8 	 5 5	 
!%%	 4 	 A	 	 $	 <	  +$'%	   5! "
0!''## #B
!"	:-'8-
- 1	 ;	  4! !$!	  . 5! = 30!C *  
>$!!"#$	8-
& !$!#	2	4	<	=!! !$!			*	@$	5	##		!	
<	 !,	 2	 5	 	 $	 <	 #!$	 +	 4! !$!	 	 $	 	 
1	 ;  #'0  !% !D	'E   11 
$#10!!%5!'5"#$$%"&' 	.&--'.&&(
 1	;	@$	5	* $		!,	2	=!! !$!		<!	5	5		
6'@	 F	 #	 < 5	 !G$$	 = <	 "	 	 	 *	 51	 	 	 =	
$	5		@3	!"	6	$		4! !$!		$	<(
5! !%! $#1C    !% !D)	.'0E  11 
$$#10!!%5!'5"#$$"&$(	&'&(.
 /	 < *	  !!	 < 5	 1 !!$	 5 	 6	  	  	 <	
,	 F	 =,	 F	 F!!	 =	 A	  *	  ?	 
 < )
*! !!%##0!##$$#1!%$$ "
0!  !1%!#$#$'	&):
 4$ 	 4 +	 	 	 5!	 	 	 < =	 5!	 4 	 
	<;3%#!!% ! !$%%##1!%
!#"5!'5	

	.))'.)).
( +	 6 5	 +"!	 +	 *	 4 
	  $$	 < 4 ( 5 !1$ # %!
#1!!% !"5!5)*	:&':&8
) !!	 * 5	  $	   5#1! !% 5!'5 " 0  !  
0 ! !$! #"&+	.'.8
. =%	  5	 $$A	  	 =!	 	 
	 > <	 $	 6	  2	 + 5 
67H%!5!'5"! $$	:8'
:(
: 	F		 *	 *!	 =		 >	 !!1	 6	 	 <	 6	 *	 
?	 F ( 5  $$  ,  0  !# " 5! 5 
 $0$	
$	)')-
8 	  
	 6	 3	 <! 	 2	 *1	 	 ;!	 3	 6%$	 	 
$	 @	 
$	 .5!'5' *!!$ !% 5**( 3%$#  !%!#
 $50$',	.().
Page 15 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 15
- 5	 3 5	 	  	 4!	 *	 41	 6	  
$	 
  
5!'5967 #! $GC  !1$ !#!# !$!B "& "-. 
  (	
('(&
& +	 6 5	 $$	 < 4 ( $  $!C 5! 5 #1! 
!-	-8'-&
 $		!		+0	<	4		;!	3	*!	+)
%!5!'5#1!5!'#!067-*	))')8
 $	 	 !	 	 ;!	 3	  *!	 + ( #$ 0 !% 5!'5
#1!067!# $	-.'-:
 ?!0	5	 !	 ;	 =	 	=	 2	 6!	 @	 *!	F <	 =	  )
!$#$#!%5!5"! ! !$!$$!##1!0
67/*	::8
( 
!	 	 ,"	 < 5	  <	  ) !  !'0  !% $$'!$#$
0!%! !' !#!%"&'	.):'..)
) *$#"!		 $$	 <5 &&.5!  ! !%0    !!'# !
%#(+	(-('(-:
. !	 = 	  !	 5 5 5+0C  0 !% $!  
%%#!%!%0 !#!/&
.+	-)'-.
: !	55	 !	= &&-5!!%!  !  ! %#
 	'&
8 *!$$	6	2	<	$!		2"!	=	=!A		!	5	!'
2!	<		2	6#	2	1!$%	@8
$	%%%#1#$
!"0#!# 
-.
%0)+*	):'..
- =!A		$!		6#	2	*!$$	6	!	5	!'2!	<		5	
	 	  1! $%	 @ 8  7*+G $!  #$ ,!"%$!, !!$ %!
!!$'#$ !'$#!
-.
%0)
+*	:8'8-
& *!G	>	=!A		*!$$	6	!!	>	$!		$	5	@!!1	>	5	
<			 #	<	1!$%	@		6+:5 !%
$00$ #G !$% !0!!%636	
 #$0!!!"&
+	('((
( 6#	2	=!A		$	5	*!$$	6	2!,"	6	$!			
	 =$	 	 	 <	 	 *	  1! $%	 @ 85$'#$ ! %!
G# !0# #$$! #  %! #!1!$$  0$ $#!
	
&&)	.(
( $		#0		 	;<	5	@	#!	.6436C%$$
! !'$#! !%$	)..*	))('))8
( 4!	6	 ! 	8%$#!%'$"#!# !#!'
"#$#	
0)%0.(	--'-&
(( 1	;	4	<		*	!$!#	2	=!! !$!		##		$	
2 +		;	 !	 <	5		 @$	5	/0	 @	;$		 1
!	 5	 !G	 
	 	 @ 3	!"	 6	 +##$	  5	 $	 	 $	 <	
4! !$!		#!$	+3!D)	.'0E 110!
!%5!"C$! !!,%#!!%!$$0!1$0$
 #$#$1$! #"&$*	.('.-
() $	<		<	!	3	$	<	!$$	>		<<	2,	
<	*$	=	6"		6		#$!	<(6$$$#
!% $!, !$#$ , % $0C ! %%#  !!$! %%# 
%#!B&	)8'.&
(. *	2	=%%	4			 +$	 :5#	 !!!
!%!"0!#11!.I' ! ##$!
&	(&'(&&
(: *!,	  	  4!	 2 < &:. ('3!!$!'#'('!#!#$
+H$0	%"&* 	::'::.
Page 16 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 16
(8 $	6	2#"	(#C!,!"!	

0)%0.	.&'::
(- $$	 <	 !$$!,	
5 2,0# %$ %! !1$!% 
%# #! ! 6532 %! # $0  %!  G#$! 
0!"&$*	8&'8)
(& <#"		!			6	+	5		<	!#",$$		!"	
<+		F	5$	+
	,#"		21	5<	1!		 		
#=	
<	;"	5 :5$$!#!$!!%5/=5"
#10$$'!$#$0!!% !' !#!,67
(	-.-
) #$	<>	$!	
	#!	=	2			+	>#		?		
	;	0	5=	4	2	5$	6	
1!	@4	!	
: #!$ 5$$!# *!#! 0,  56'   
$!63@6!#"6=6!="&*	&('.
) 5"			F	$$	<5)$$'!$#$0!!% !' !
#!C !!,$"&	')
) 5	35	!	@	*!$!	
	$!		41	6	
$	
	6	
5 8 3%#! !% $$ !$#$ 0! !%  5!'5967 #! $G

%	(8'(((
 
Page 17 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Tyr10&
Asp11&
Phe16&
Phe19&
Trp34&
Phe35&
Hydrophobic&
groove&
Disordered&
linker&
Tyr8&
GST‐TPX21‐43 variant 
 
 
40 
 
30 
 
25 
GST 
Aurora‐ACA 
A 
B 
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
-14
-12
-10
-8
-6
-4
-2
0
-1.4
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
!
"
#
$%
&
'
"
Molar Ratio
(
"
#
$%
)
*
$'
+*
,+
-.
/'
"
0#
.
0
0.0 0.5 1.0 1.5 2.0 2.5
-20
-18
-16
-14
-12
-10
-8
-6
-4
-2
0
2
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
-10 0 10 20 30 40 50 60 70 80 90 100110120
Time (min)
!
"
#
$%
&
'
"
Molar Ratio
(
"
#
$%
)
*
$'
+*
,+
-.
/'
"
0#
.
0
WT  
F19A 
C 
D 
Page 18 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Y‐pocket 
35 hits 
59 % 
F‐pocket 
10 hits 
17 % 
W‐pocket 
1 hit 
2 % 
Elsewhere 
13 hits 
22 % 
Y‐pocket 
35 hits 
 
F‐pocket 
10 hits 
 
B 
C 
A 
Page 19 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
N
S
O
F
Cl
F
Cl
HS R
NH
O
S
S
R
A 
B 
Page 20 of 22ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
H2N
S
N
N
F
F
F
N
HN
OH
F
F
OH
S
HO
O
S
N
O
O
S
S
NH2
Fragment 5 
PDB code: 5ORR  
Fragment 11 
PDB code: 5ORY 
Fragment 12 
PDB code: 5ORZ 
Fragment 14 
PDB code: 5OS1 
Fragment 18 
PDB code: 5OS5 
Fragment 20* 
PDB code: 5OSD 
O
O
OH
Cl
Page 21 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
0.0 0.5 1.0 1.5 2.0 2.5
-40
-35
-30
-25
-20
-15
-10
-5
0
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
!
"
#
$%
&
'
"
Molar Ratio
(
"
#
$%
)
*
$'
+*
,+
-.
/'
"
0#
.
0
0.0 0.5 1.0 1.5 2.0 2.5
-50
-40
-30
-20
-10
0
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
!
"
#
$%
&
'
"
Molar Ratio
(
"
#
$%
)
*
$'
+*
,+
-.
/'
"
0#
.
0
0.0 0.5 1.0 1.5 2.0 2.5
-30
-20
-10
0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
!
"
#
$%
&
'
"
Molar Ratio
(
"
#
$%
)
*
$'
+*
,+
-.
/'
"
0#
.
0
0.0 0.5 1.0 1.5 2.0 2.5
-40
-20
0
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
0.8
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
!
"
#
$%
&
'
"
Molar Ratio
(
"
#
$%
)
*
$'
+*
,+
-.
/'
"
0#
.
0
0.0 0.5 1.0 1.5 2.0 2.5
-38
-36
-34
-32
-30
-28
-26
-24
-22
-20
-18
-16
-14
-12
-10
-8
-6
-4
-2
0
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
!
"
#
$%
&
'
"
Molar Ratio
(
"
#
$%
)
*
$'
+*
,+
-.
/'
"
0#
.
0
0.0 0.5 1.0 1.5 2.0 2.5
-60
-50
-40
-30
-20
-10
0-1.6
-1.4
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
!
"
#
$%
&
'
"
Molar Ratio
(
"
#
$%
)
*
$'
+*
,+
-.
/'
"
0#
.
0
Fragment number 
Control  DMSO  5  11  12  14  18  20 
Aurora‐A/TPX2 
Kd (μM) 
0.27  0.30  0.60  0.62  0.39  0.38  1.39  3.76 
Error  0.04  0.06  0.05  0.06  0.04  0.04  0.14  0.51 
Kd, dissocia5on constant measured between Aurora‐A and TPX2 by ITC; Error, either the standard devia5on between mul5ple Kd values 
(control, DMSO) or the error of the ﬁΤed curve calculated by Origin soςware (fragments); Control, the ‘standard’ aﬃnity between Aurora‐A 
and TPX2; DMSO, in the presence of 5 % DMSO; PM0XX, in the presence of fragment at a concentra5on of 3/4x its Kd at 5 % ﬁnal DMSO. 
Control and DMSO measurements were repeated at least in triplicate, fragment compe55on measurements were performed once each. 
5  11  12  14  18  20 
A 
B 
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